AskGene Limited, a Camarillo, CA- and Nanjing, China-based clinical-stage biopharmaceutical firm specializing in discovery and growth of revolutionary organic medicine, closed a USD 20m Series A financing.
The spherical was led by Qiming Venture Partners and TF Capital.
Proceeds from the financing might be used to advance scientific growth of its pipeline of revolutionary therapeutic candidates and growth of SmartKine® cytokine prodrug platform.
Led by Jeff Lu, Chief Executive Officer, AskGene is advancing immunotherapies for cancers and autoimmune illnesses. Through its SmartKine® platform expertise and pipeline packages, the corporate goals to realize its goal of modulating immune system at a illness website with selectivity and precision. Additional scientific stage packages embody ASKB589 (an anti-CLDN 18.2 antibody in part I/II) and ASKG712 (an anti-VEGF antibody-ANG2 antagonist peptide fusion molecule in part I).